Alkermes (ALKS) received a Hold rating and a $28 price target from H.C. Wainwright analyst Douglas Tsao today. The company’s shares closed yesterday at $22.03, close to its 52-week low of $22.02.
Tsao observed:
“Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%).”
According to TipRanks.com, Tsao is a 3-star analyst with an average return of 1.8% and a 51.6% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Minerva Neurosciences, and Revance Therapeutics.
Alkermes has an analyst consensus of Hold, with a price target consensus of $31.78.
See today’s analyst top recommended stocks >>
The company has a one-year high of $51.70 and a one-year low of $22.02. Currently, Alkermes has an average volume of 1.1M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
